Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Liver, Pancreas and Biliary Tract

Systemic inflammation as fuel for acute liver injury in COVID-19

Maria Effenberger a,1, Christoph Grander a,1, Felix Grabherr a, Andrea Griesmacher c, Thomas Ploner a,2, Frank Hartig a, Rosa Bellmann-Weiler b, Michael Joannidis a, Heinz Zoller a, Günter Weiss b, Timon Erik Adolph a, Herbert Tilg a,∗

a Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria
b Department of Internal Medicine II, Infectious Disease, Pulmonology & Rheumatology, Medical University of Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria
c Central Institute for Medical and Chemical Laboratory Diagnosis, Medical University of Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria

A R T I C L E   I N F O

Article history:
Received 12 June 2020
Accepted 3 August 2020
Available online 10 August 2020

Keywords:
Acute phase protein
COVID-19
Cytokines
Interleukin-6
Liver damage
SARS-CoV2

A B S T R A C T

Background: A cytokine storm conceivably contributes to manifestations of coronavirus disease (COVID-19). Inflammatory cytokines such as interleukin-6 (IL-6) cause acute liver injury while serum detectability indicates systemic inflammation.

Aims: We explored a link between systemic IL-6, related acute phase proteins and liver injury in hospitalized COVID-19 patients.

Methods: 655 patients with suspected COVID-19 were screened in the emergency department at the University Hospital of Innsbruck, Austria, between February and April 2020. 96 patients (∼15%) were hospitalized with COVID-19. 15 patients required intensive-care treatment (ICT). Plasma aminotransferases, alkaline phosphatase, bilirubin, and gamma glutamyl transferase, as well as IL-6, C-reactive protein (CRP), ferritin and lactate dehydrogenase (LDH) were determined by standard clinical assays.

Results: Of all hospitalized COVID-19 patients, 41 (42%) showed elevated aspartate aminotransferase (AST) concentration. COVID-19 patients with elevated AST exhibited significantly higher IL-6 (p < 0.001), ferritin (p < 0.001), LDH (p < 0.001) and CRP (p < 0.05) serum concentrations compared to patients with normal AST. Liver injury correlated with systemic IL-6 (p < 0.001), CRP (p < 0.001), ferritin (p < 0.001) and LDH (p < 0.01) concentration. In COVID-19 patients requiring ICT, correlations were more pronounced.

Conclusion: Systemic inflammation could be a fuel for hepatic injury in COVID-19.

© 2020 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

In December 2019, a series of patients with pneumonia caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported from Wuhan, Hubei province in China [11]. Since then, Coronavirus Disease 2019 (COVID-19) has spread globally with more than 6,300,000 infections and, by date, more than 370,000 deaths worldwide. The typical symptoms of SARS-CoV-2 infection, such as fever, cough, sore throat, or dyspnea, are well recognized and have been widely described [2–6] while also organs beyond the respiratory tract may be affected [7,8].

SARS-CoV-2 is a beta-coronavirus that is closely related to severe acute respiratory syndrome coronavirus (SARS-CoV) [9]. Both viruses use the angiotensin-converting enzyme-related carboxypeptidase (ACE2) as receptor to gain entry into mammalian cells [10]. Previous studies found that ACE2 expression is related to the severity of acute respiratory distress syndrome (ARDS) caused by SARS-CoV infection, and mediates the production of cytokines in ARDS [11,12]. Massive release of pro-inflammatory cytokines results in a cytokine storm (also termed cytokine release syndrome (CRS)) which is characterized by elevated C-reactive protein (CRP), interleukin 6 (IL-6), lactate dehydrogenase (LDH) and ferritin concentration that is accompanied by organ dysfunction (such as

https://doi.org/10.1016/j.dld.2020.08.004
1590-8658/© 2020 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ARDS, progressive liver damage and liver failure). As such, the systemic release of pro-inflammatory cytokines seems to be a driver of disease progression in COVID-19 [13–15].

The impact of SARS-CoV-2 on liver disease is poorly understood [16,17]. Several studies reported clinical features of liver injury in COVID-19 patients [3–6,18–20] with elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) in 14% to 53% of COVID-19 patients [3,5,6], which could be an indicator for severe pneumonia [21]. Similarly, delayed hospital admission after illness onset was associated with increased risk of liver injury in patients with COVID-19 [22]. Notably, hepatic infiltration of lymphocytes, centrilobular sinusoidal dilation and patchy necrosis could be observed in COVID-19 patients [23,24], and SARS-CoV-2 might directly bind to ACE2-expressing cholangiocytes [25]. However, the origin of liver injury remains unresolved and could be related to systemic inflammation, SARS-CoV-2 infection or drug administration [26].

IL-6 is a potent cytokine with diverse functions during hepatic inflammation and regeneration [27]. IL-6 serves inflammatory (danger) signaling and (because of its half life) better indicates systemic inflammation when compared to other cytokines, such as Interleukin-1 beta (IL-1β) or TNF-alpha (TNF-α) [28]. The aim of this study was to explore a link between systemic inflammation and liver injury in COVID-19.

### 2. Methods

#### 2.1. Patients

The study was performed at the University Hospital of Innsbruck, Austria, the only referral hospital in Tyrol, Austria. From February 26<sup>th</sup>, 2020 to April 21<sup>st</sup>, 2020, 655 patients with suspected COVID-19 were evaluated. 96 patients were diagnosed with COVID-19 based on the World Health Organization interim guidance [29]. 81 patients were hospitalized without the need for intensive care, while 15 patients required intensive care treatment on admission day. None of the included individuals was admitted to an intensive care unit (ICU) 3 months prior to study inclusion. 8 of 96 patients showed evidence of hepatic steatosis by ultrasonography (6/8 diagnosed with metabolic associated liver disease [30]) 3 to 12 month prior to hospitalization. No other chronic liver disease (such as chronic viral hepatitis, alcoholic liver disease, immune-mediated liver disorders or hemochromatosis) were documented in any patient and all patients had normal liver enzymes documented in previous biochemical studies (8.9 months ± 6.1months prior to hospitalization). None of the patients received any antibiotic or antiviral therapy in the past 3 months. Fever was defined as body temperature ≥ 37.3°C and dyspnea was defined by a respiratory rate ≥ 20 breaths/minute and resting finger oxygen saturation ≤ 93% [31]. Gastrointestinal symptoms were recorded based on medical history taken at hospital admission. Diarrhea was defined by loose stools > 3 times per day, vomiting was defined by ≥ 1 per day. All reported parameters were collected on admission day.

#### Table 1

| Patient characteristics in Covid-19 patients admitted to general ward (non ICU) or ICU. |
|---------------------------------------------|
| Overall | Non ICU | ICU | non ICU vs ICU |
|---------|----------|-----|----------------|
| Age [years] | 60.69 ± 18.915 | 60.98 ± 20.12 | 59.13 ± 10.54 | 15 ns |
| Females (%) | 36 (37.5) | 32 (39.5) | 4 (26.7) | 15 ns |
| Smoker (%) | 11 (13.4) | 9 (11.8) | 2 (15.4) | 13 ns |
| Allergies (%) | 21 (23.3) | 17 (22.1) | 4 (30.8) | 13 ns |
| Malignant disease (%) | 9 (9.9) | 9 (11.5) | 0 (0) | 13 ns |
| Hypertension (%) | 46 (50.5) | 38 (48.7) | 8 (61.5) | 13 ns |
| Diabetes (%) | 18 (19.8) | 15 (19.2) | 3 (23.1) | 13 ns |
| Chronic liver disease* (n=6) (%) | 8 (9.8) | 6 (6.4) | 3 (23.1) | 13 ns |
| Heart disease (%) | 20 (122.2) | 18 (23.4) | 2 (15.3) | 13 ns |
| Pulmonary disease (%) | 10 (11) | 7 (9) | 3 (23.1) | 13 ns |
| Immunosuppression (%) | 3 (3.3) | 1 (1.3) | 2 (15.4) | 13 ns |
| Fever ≥ 37.3°C (%) | 69 (75.8) | 56 (71.8) | 13 (100) | 13 0.033 |
| Dyspnea (%) | 45 (50) | 34 (44.2) | 11 (84.6) | 13 0.014 |
| Cough (%) | 80 (88.9) | 68 (88.3) | 12 (92.3) | 13 ns |
| Sputum (%) | 24 (26.7) | 22 (28.6) | 2 (13.3) | 13 ns |
| Hemoptysis (%) | 5 (6.6) | 5 (6.5) | 0 (0) | 13 ns |
| Sore throat (%) | 26 (28.9) | 23 (29.9) | 3 (23.1) | 13 ns |
| Nasal obstruction (%) | 18 (20) | 15 (19.5) | 3 (23.1) | 13 ns |
| Muscle ache (%) | 60 (66.7) | 50 (64.9) | 10 (76.9) | 13 ns |
| Fatigue (%) | 61 (67.8) | 51 (66.2) | 10 (76.9) | 13 ns |
| Nausea (%) | 14 (15.6) | 13 (16.9) | 1 (7.7) | 13 ns |
| Vomiting (%) | 7 (7.8) | 7 (9.1) | 0 (0) | 13 ns |
| Diarrhea (%) | 16 (17.8) | 14 (18.2) | 2 (15.4) | 13 ns |
| Imaging finding (%) | 55 (61.8) | 43 (56.6) | 12 (92.3) | 13 0.012 |
| Antibiotic therapy on admission day (%) | 14 (15.7) | 11 (14.5) | 3 (23.1) | 13 ns |
| Antiviral therapy on admission day (%) | 1 (1.2) | 1 (1.4) | 0 (0) | 13 ns |
| Antibiotic therapy during hospital stay (%) | 59 (66.3) | 46 (60.5) | 13 (100) | 13 0.04 |
| Antiviral therapy during hospital stay (%) | 30 (34.5) | 17 (23) | 13 (100) | 13 <0.001 |
| Elevated AST (%) | 41 (42.7) | 32 (39.5) | 8 (60) | 15 ns |
| Hospital stay (days) | 19.4 ± 7.2 | 8.7 ± 6.3 | 36.2 ± 15.7 | 15 <0.001 |
| ICU stay (days) | 24 ± 13.2 | 81 | 24 ± 13.2 | 15 <0.001 |
| Mortality (%) | 7 (7.3) | 5 (6.2) | 2 (15.4) | 15 0.04 |

*MAFLD (n=6) **chronic hepatitis B infection (n=2).

Patient characteristics in Covid-19 patients admitted to general ward (non ICU) or ICU. Data are expressed as case numbers (percentage) or mean ± standard deviation. AST, aspartate aminotransferase; ICU, intensive care unit; MAFLD, metabolic associated fatty liver disease.
Table 2
Laboratory parameters in Covid-19 patients admitted to general ward (non ICU) or ICU.

| Parameter                  | Non ICU | ICU |
|----------------------------|---------|-----|
| n                          | 81      | 15  |
| Bilirubin [mg/dl]          | 0.45 (0.3-0.67) | 0.641 ± 0.30 | 15 | ns |
| AST [U/l]                  | 34 (23-56.5) | 54.73 ± 18.40 | 15 | 0.02 |
| ALT [U/l]                  | 25 (17-42) | 44.93 ± 24.83 | 15 | ns |
| Maximum AST [U/l]          | 57.4 ± 44.8 | 179.9 ± 121.1 | 15 | <0.001 |
| Maximum ALT [U/l]          | 59.1 ± 32.9 | 178.3 ± 116.9 | 15 | <0.001 |
| Maximum AST after hospital admission (days) | 3.1 ± 2.0 | 11.7 ± 5.6 | 15 | <0.001 |
| Maximum ALT after hospital admission (days) | 3.9 ± 2.1 | 15.5 ± 6.9 | 15 | <0.001 |
| Liver stiffness [kPa]       | 4.8 ± 2.7 | 0 ± 3.2 | 15 | ns |
| CK [U/l]                   | 111.3 ± 81.5 | 107.6 ± 52.1 | 15 | ns |
| Troponin T [U/l]           | 16.8 ± 9.2 | 10.9 ± 6.2 | 15 | ns |
| Creatinine [mg/dl]         | 0.85 ± 0.28 | 0.84 ± 0.21 | 15 | ns |
| LDH [U/l]                  | 256.6 ± 95.9 | 439.2 ± 176.2 | 15 | <0.0001 |
| GGT [U/l]                  | 38 (25-67) | 47 (27-82) | 15 | ns |
| AP [U/l]                   | 61 (47-72.5) | 60 (50-69) | 15 | ns |
| CRP [mg/dl]                | 3.28 (0.38-7.35) | 12.982 ± 9.33 | 15 | <0.001 |
| PCT [μg/l]                 | 0.08 (0.6-0.23) | 0.28 (0.2-0.7) | 15 | <0.001 |
| IL-6 [ng/l]                | 18.6 (5.3-68.3) | 92.2 (18-171.6) | 15 | 0.003 |
| Leukocytes [10³/l]         | 5.821 ± 1.94 | 7.033 ± 3.25 | 15 | ns |
| Hb [g/l]                   | 133.26 ± 17.31 | 131 ± 21.86 | 15 | ns |
| Platelets [10⁹/l]          | 220 (171-294.5) | 227.67 ± 92.77 | 15 | ns |
| Prothrombin time [%]       | 1 (0.9-1) | 1.02 ± 0.11 | 15 | ns |
| Ferritin [μg/l]            | 525 (217-982) | 1650.67 ± 1187.12 | 15 | <0.001 |

Laboratory parameters of Covid-19 patients admitted to ICU or general ward (non ICU). Quantitative data were expressed as means ± standard deviation if normally distributed. For non-normally distributed variables, data are shown as medians with first and third quartiles. AP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CK, creatinine kinase; CRP, C-reactive protein; GGT, gamma-glutamyl transferase; Hb, hemoglobin; ICU, intensive care unit; IL-6, interleukin 6; LDH, lactate dehydrogenase; mg/dl, milligrams/deciliter; μg/l, micrograms/liter; PCT, procalcitonin; U/l, Units/liter.

Fig. 1. IL-6 correlates with AST and is increased in patients with impaired liver function. (A) IL-6 and AST levels correlate in all hospitalized patients. (B) IL-6 levels correlate with AST concentration in non ICU and ICU patients. Displayed are IL-6 concentrations in patients with normal AST and elevated AST in (C) non ICU and (D) ICU patients. Data are shown as mean ± SEM, n: (C-D) *p<0.05; **p<0.01; ***p<0.001 according to Spearman correlation or Student’s t-test. AST, aspartate aminotransferase; ICU, intensive care unit; IL-6, interleukin 6.
2.2. SARS-CoV2- analysis

Laboratory confirmation of SARS-CoV-2 infection was performed using previously described real-time polymerase chain reaction [4] as recommended by the Centers for Disease Control and Prevention (DeKalb, GA).

2.3. Liver parameters

Elevated liver tests were defined by the AST $\geq$ 50 Units/liter (U/l), ALT $\geq$ 50 U/l, gamma-glutamyl transferase (GGT) $\geq$ 71 U/l, alkaline phosphatase (AP) $\geq$ 129 U/l and total bilirubin $\geq$ 1.28 U/l assessed on admission day. In COVID-19 consensus on liver injury classification by biochemical means is lacking. Therefore, patients displaying AST concentrations ($\geq$ 50 U/l) was considered to be increased (as in other clinical situations).

2.4. IL-6 and acute phase proteins

IL-6, CRP, LDH and ferritin were determined by Cobas 8000, (Roche, Basel, Switzerland) according to the manufacturer’s specification. The lower detection limit of the assay for IL-6 is $<$ 5 nanograms/mililiter (ng/ml), for CRP 0.05 milligrams/deciliter (mg/dl) and 20 micrograms/liter (μg/l) for ferritin. The established cut-off value for CRP is 0.50 mg/dl, for LDH 100 U/l and for ferritin 400 μg/l.

2.5. Creatininkinase (CK), Troponin T and creatinine (Crea)

CK, Troponin T and Crea were determined by Cobas 8000, (Roche, Basel, Switzerland) according to the manufacturer’s specification. The lower detection limit of the assay for CK is $<$ 10U/l, for Troponin T is 5 nanograms/deciliter (ng/dl) and 0.3 micrograms/deciliter (mg/dl) for Crea. The established cut-off value for CK is 190 U/l, for Troponin T is 50 ng/dl and 1.2 mg/dl for Crea.

2.6. Data analysis

Data were expressed as mean ± standard error of mean or as median with first and third quartiles. For comparing quantitative variables, the Student’s t-test or the non-parametric Mann-Whitney U or Wilcoxon signed-rank test were used as appropriate. Normality of distribution was determined by Kolmogorov-Smirnov test. The correlation analysis was estimated using the Spearman’s p coefficient A p-value $<$ 0.05 was considered as statistically significant. All statistical analyses were performed using SPSS Statistics v.22 (IBM, Chicago, IL) and GraphPad PRISM 5 (La Jolla, CA).

2.7. Ethical consideration

The study protocol was approved by the institutional ethics commission with an amendment to AN2017-0016 369/4.21 and informed consent was obtained, if applicable, from each patient included in the study. The study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki (6th revision, 2008) as reflected in a priori approval by institutional ethics commission.

3. Results

3.1. Clinical characteristics of hospitalized COVID-19 patients

The mean age of patients included into our study was 60.69 years with 37.5% (n=36) females. Patients characteristics are listed in Table 1. Most COVID-19 patients reported fever (75.8%), cough (88.9%), muscle pain (66.7%) and fatigue (67.8%), whereas dyspnea was noted in 50% of patients. Gastrointestinal symptoms like nausea, vomiting, and diarrhea were present in 15.6%, 7.8% and 17.8%, respectively. Importantly, 61.8% of patients showed typical radiologic findings in imaging studies (chest X-ray or computed tomography). Most patients reported chronic diseases like hypertension (50.5%), type 2 diabetes (19.8%), pulmonary disease (11%) and 13.4% reported a history of smoking. During hospitalization (i.e. after liver enzyme testing) 66.3% of patients received antibiotic therapy with cephalosporines in all cases to cover secondary infections, and 42.7% of patients received anti-viral therapy with favipiravir. Important to note, only 3 patients received antibiotic therapy and none received anti-viral therapy ahead of admission. On admission day, 32 non-ICU patients (39.5%) displayed elevated AST, 60% of patients at the ICU showed elevated AST, and no patient showed clinical or biochemical features of fulminant hepatitis (Table 1). Skeletal muscle, myocardium, and kidney might all be sources of AST, therefore AST levels were correlated with CK (non significant (ns), data not shown), Troponin T (ns, data not shown) and Crea (ns, data not shown). ALT was elevated in only 5 patients on admission day. These findings are in line with other studies, suggesting ALT elevation appears at a later time-point during COVID-19 [21,22,26]. None of the patients showed elevated Bili, GGT and AP at a such early stage of disease. ICU patients displayed higher frequencies of fever (p<0.033), dyspnea (p=0.014) and imaging findings (p=0.012) at admission, compared to non ICU patients (Table 1). During hospitalization none of the non ICU-patients was transferred to the ICU. The length of hospital stay was significantly longer in ICU patients (p<0.001) and mortality rate was significantly higher in ICU patients (p<0.001) (Table 1). Patients admitted to the ICU showed significantly higher levels of AST (p=0.02), CRP (p<0.001), LDH (p<0.001), procalcitonin (PTC, p<0.001), ferritin (p<0.001) and IL-6 (p=0.003) (Table 2). Furthermore maximum AST (p<0.001) and ALT (p<0.001) during hospital stay were significantly higher and peaked significantly later during disease course (p<0.001) in ICU patients (Table 2).

3.2. Liver damage correlates with IL-6 and acute phase proteins

IL-6 positively correlated with AST in all patients (r²=0.481, p<0.001, Fig. 1A). In both ICU and non-ICU patients a positive correlation could be observed (Fig. 1B) with more pronounced effects in ICU patients (r²=0.610, p=0.016). Splitting our cohort in individuals with increased (≥ 50 U/l) and normal (<50 U/l) AST concentration, we could observe higher IL-6 levels in non ICU patients (p<0.001, Fig. 1C) as well as ICU patients (p=0.048, Fig. 1D) with elevated AST. IL-6 didn’t correlate with ALT, GGT, Bilirubin and AP on admission day.
Likewise, CRP correlated with AST in all hospitalized patients ($r^2=0.38$, $p<0.001$, Fig. 2A). Both ICU ($r^2=0.539$, $p=0.038$, Fig. 2B) and non ICU ($r^2=0.328$, $p=0.003$, Fig. 2B) patients displayed a correlation with CRP and AST at admission. In individuals with liver damage, CRP levels were higher in non-ICU patients ($p<0.001$, Fig. 2C), whereas we could not observe any significant difference in patients at the ICU ($p=0.256$, Fig. 2D). Similarly, ferritin concentration correlated with AST ($r^2=0.6$, $p<0.001$, Fig. 3A), although in ICU patients this effect was more distinct ($r^2=0.84$, $p<0.001$, Fig. 3B) compared to non-ICU patients ($r^2=0.578$, $p<0.001$, Fig. 3B). In both non-ICU and ICU patients, individuals with elevated AST seem to have higher concentrations of ferritin (Fig. 3C and D). Furthermore, LDH concentration correlated with AST ($r^2=0.6$, $p<0.001$, Fig. 4A), although in ICU patients this effect was more distinct ($r^2=0.84$, $p<0.001$, Fig. 4B) compared to non-ICU patients ($r^2=0.578$, $p<0.001$, Fig. 4B). In Non-ICU patients LDH levels were higher in individuals with increased AST ($p<0.01$, Fig. 4C), whereas ICU patients with altered AST only tended to be higher ($p=0.162$, Fig. 4D). Furthermore, maximum AST and ALT levels correlated directly with IL-6, Ferritin and CRP in non-ICU patients (Fig. 4E). Furthermore, we performed a longitudinal comparison of AST, ALT and Bilirubin. Liver parameters were more pronounced in patients with higher IL-6 levels. Data are now presented in Supplementary Fig. 1. We compared outcome data with IL-6 and acute phase protein levels. IL-6 was positively correlated with duration of hospital stay ($r^2=0.109$, $p=0.01$ Supp. Fig. 2A), ICU stay ($r^2=0.162$, $p=0.001$ Supp. Fig. 2A), days of mechanical ventilation ($r^2=0.146$, $p=0.001$ Supp. Fig. 2A), and negatively correlated with mean arterial pressure ($r^2=0.082$, $p=0.01$ Supp. Fig. 2A). CRP also showed a significant correlation whereas LDH, showed no significant correlation with mean arterial pressure. Supp. Fig. 2b and c. Ferritin was not significantly correlated to patients outcome (data not shown).

4. Discussion

Previous studies reported signs of liver injury by biochemical and histologic means in COVID-19 patients [4,19,21–23]. However, the origin of hepatic damage in COVID-19 is poorly understood and potentially involves systemic inflammation, viral replication or drug-induced liver injury. Today, we lack evidence for SARS-CoV-2 replication in the liver and our study renders drug-induced liver injury as cause of elevated liver enzymes very unlikely. We rather found a direct correlation between systemic inflammation (indicated by IL-6, CRP and ferritin) and liver damage. IL-6 pro-
duction may stem from immune cells [32] fibroblasts, endothelial cells [33] and hepatocytes [27,34] which orchestrates an hepatic acute phase response [32,35,36]. While IL-6 signaling impinges on hepatic regeneration [27], clinical studies (that for example tested the effect of IL-6 administration in cancer patients) demonstrated a critical role of this pathway in hepatic injury and hepatotoxicity [37–39]. In line with a critical impact of systemic inflammation and specifically IL-6 on liver injury, we noted a direct correlation between acute phase proteins and IL-6 in the serum of COVID-19 patients with elevated AST. Based on previous reports and our study, with the limitation of the Cross-sectional design, we propose that the systemic inflammatory response to SARS-CoV-2 infection to COVID-19 patients serves as a fuel of hepatic injury. In line with this, our findings appeared more pronounced in COVID-19 patients with a more severe CRS (i.e. that required intensive care measures). Vice versa, tocilizumab, a recombinant humanized monoclonal antibody targeting the human IL-6 receptor, reversed liver injury during CRS that was induced by non-infectious means (i.e. CAR-T cell therapy) [40,41].

While experimental evidence suggests that blockade of an inflammatory response in SARS-CoV-2-related CRS improves the course of infection [42,43], clinical trials are pending. In the previous MERS-CoV epidemic, IL-6 and other inflammatory cytokines, such as IL-2 have been identified as key players during infection and trigger hepatic injury [44,45]. In COVID-19 patients, elevated IL-6 concentrations (amongst others) have been described [46] and a cytokine signature was indeed associated with loss of lung function, lung injury and outcome [47]. As such, it appears that SARS-CoV-2 potently triggers a systemic cytokine response that is detrimental for some patients (as in CRS) while factors that control this response remain undetermined. This cytokine response, but probably not viral burden, seems to play the key role in disease severity and patient outcome [48].

Conflict of interest

All authors declare no conflict of interest.

Funding

This study is supported by the excellence initiative VAScage (Centre for Promoting Vascular Health in the Ageing Community), an R&D K-Centre (COMET program - Competence Centers for Excellent Technologies) funded by the Austrian Ministry for Transport, Innovation and Technology, the Austrian Ministry for Digital and Economic Affairs and the federal states Tyrol, Salzburg and Vienna.

Acknowledgments

No funders were involved in the study concept, design, data analyses, writing of this manuscript, or in the decision to submit this work for publication.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.dld.2020.08.004.

References

[1] Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199–207.
[2] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33.
[3] Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.
[4] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
[5] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13.
[6] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.
[7] Effenberger M, Grabherr F, Mayr L, et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut 2020;69:1543–4.
[8] Sultan S, Altayar O, Siddiqui SM, et al. AGA institute rapid review of the GI and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology 2020;159:320–334.e7.
[9] de Wit E, van Doremalen N, Fauzalan D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14:523–34.
[10] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020.
[11] Rockel B, Baas T, Zornetzer GA, et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 2009;83:7062–74.
[12] He L, Ding Y, Zhang Q, et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol 2006;210:288–97.
[13] Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4.
[14] Moore BJ, June CH. Cytokine release syndrome in severe COVID-19. Science 2020;368:473–4.
[15] Giamarellos-Bourboulis EJ, Neta MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbiol 2020;27:992–1000.e3.
[16] Bangash MN, Patel J, Pareek D, COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol 2020;5:529–30.
[17] Xie H, Zhao J, Lian N, et al. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. Liver Int 2020;40:1321–6.
[18] Wu Z, McGoogan JM. Characteristics and of important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020.
[19] Lescure FX, Boudama L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis 2020;20:697–706.
[20] Zhang Y, Zheng L, Liu L, et al. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver Int 2020.
[21] Cai Q, Huang D, Yu H, et al. Characteristics of liver tests in COVID-19 patients. J Hepatol 2020;73:712–13.
[22] Qi X, Liu C, Jiang Z, et al. Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury. J Hepatol 2020;73:455–8.
[23] Hanley B, Lucas SB, Yould C, et al. Autopsy in suspected COVID-19 cases. J Clin Pathol 2020;73:239–42.
[24] Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 2020;33:1007–14.
[25] Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv 2020.
[26] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5:428–30.
[27] Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol 2016;64:1403–15.
[28] Neta MG, Balkwill F, Chonchol M, et al. A guiding map for inflammation. Nat Immunol 2017;18:826–31.
[29] World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. https://www.who.int/publications-detail-clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(nCoV)-infection-is-suspected. Accessed on January 31, 2020.
[30] Eslami M, Newsome PN, Anstee QM, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202–9.
[31] Zhang J, Zhou L, Yang Y, et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med 2020;8:e11–e22.
[32] Gaudie J, Richards C, Harnish D, et al. Interferon beta 2B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987;84:7251–5.
[33] Bode JC, Albecht U, Haussinger D, et al. Hepatic acute phase proteins–regulation by IL-6 and IL-1 type cytokines involving STAT3 and its crosstalk with NFκB-dependent signaling. Eur J Cell Biol 2012;91:496–505.
[34] Fielding CA, Jones GW, McLoughlin RM, et al. Interleukin-6 signaling drives inflammation in unresolved inflammation. Immunity 2014;40:40–50.
[35] Hunter CA, Jones SA, IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015;16:448–57.
[36] Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448–54.
[37] Banks RE, Forbes MA, Patel PM, et al. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. Cytokine 2000;12:388–96.

[38] Weber J, Gunn H, Yang J, et al. A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J Immunother Emphasis Tumor Immunol 1994;15:292–302.

[39] Yamaji K, Ochiai Y, Ohnishi K, et al. Up-regulation of hepatic heme oxygenase-1 expression by locally induced interleukin-6 in rats administered carbon tetrachloride intraperitoneally. Toxicol Lett 2008;179:124–9.

[40] Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020;55:105954.

[41] Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev 2019;34:45–55.

[42] Liu B, Li M, Zhou Z, et al. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 2020:102452.

[43] DeDiego ML, Nieto-Torres JL, Regla-Nava JA, et al. Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol 2014;88:913–24.

[44] Fehr AR, Channappanavar R, Perlman S. Middle east respiratory syndrome: emergence of a pathogenic human coronavirus. Annu Rev Med 2017;68:387–99.

[45] Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020;40:998–1004.

[46] Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest 2020;130:2202–5.

[47] Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol 2020;20:277.

[48] Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature 2020;583:437–40.